Compare Affirm Holdings Inc (AFRM) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs GSK plc — how do they compare? Affirm Holdings Inc trades at $76.91 (market cap $25.30B), while GSK plc trades at $50.55 (market cap $104.15B). The key difference: GSK plc is far larger — about 4.1× Affirm Holdings Inc's market cap, and GSK plc pays a 3.48% dividend while Affirm Holdings Inc pays none. Which is the better fit depends on your goals.
| AFRM | GSK | |
|---|---|---|
Market Cap | $25.30B | $104.15B |
Sector | Financials | Health |
52-Week High | $92.18 | $61.18 |
52-Week Low | $42.53 | $38.22 |
Enterprise Value | $31.91B | $124.56B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.
Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.
GSK trades at $52.96, up 1.51% today, with strong technical momentum showing bullish moving averages and neutral oscillators. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $1.36 beating estimates by 7%. Recent FDA approval for Jideytro lung cancer therapy and a $2.52 billion cost-saving initiative support growth prospects. Valuation metrics remain reasonable with P/E of 16.69 and EV/EBITDA of 9.68.
GSK presents a balanced investment case with solid fundamentals and pipeline progress offset by margin pressure risks. The company's 29.73% ROE and consistent dividend payments provide shareholder value, while competitive pressures and patent expirations require careful monitoring. Analyst consensus leans Hold (55%) with 31% Buy ratings, suggesting cautious optimism for the pharmaceutical giant's transformation under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
